Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0729233 (Thoracic)
 6,478 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The origin of the B cells of splenic marginal zones was studied using transfer experiments in rats depleted of marginal-zone cells. Cyclophosphamide given as a single dose of 500 mg/m2 was used to deplete the marginal zones. Approximately 90% depletion was still apparent 10 days after treatment. Fetal liver cells did not induce rapid repopulation of the marginal zone. Also bone marrow cells from rats depleted of recirculating lymphocytes were inefficient in this respect. Conversely, thoracic duct lymphocytes and bone marrow cells from normal rats were efficient at restoring marginal-zone cell numbers in cyclophosphamide-treated rats. Thoracic duct cells passaged through an irradiated intermediate host and collected from that host's thoracic duct were also efficient at achieving marginal-zone reconstitution. In rats receiving 1000 rd whole body irradiation, which were protected with fetal liver cell transfer, marginal zones did repopulate at about 3 weeks. It is concluded that marginal-zone B cells, after leaving primary lymphoid organs, enter the recirculating pool for a period of at least several days before settling in the marginal zone. The turnover rate of marginal-zone cells was assessed using tritiated thymidine infusion. Most marginal-zone cells were not labeled after 5 days continuous labeling suggesting that the marginal-zone B cells are not rapidly dividing.
 ...
PMID:Cells of the marginal zone of the spleen are lymphocytes derived from recirculating precursors. 697 95

Multicentric Castleman disease (MCD) is a rare lymphoproliferative disorder. Although MCD pathogenesis is unclear, studies have suggested that human herpesvirus 8 (HHV-8) may be associated with the disorder. Recent reports have identified MCD cases without viral infection. A 43-year-old woman presented to our hospital for fever and myalgia of 6 months' duration. The complete blood count revealed an elevated leukocyte count (15.1x10(3)/microL) and a decreased hemoglobin level of 10.0 g/dL. The C-reactive protein level was elevated at 276.5 mg/L. Thoracic computed tomography (CT) scans revealed bilateral axillary lymphadenopathy. There was no evidence of HHV-8, human immunodeficiency virus (HIV), or Mycobacterium infection. Histologic evaluation of a lymph node biopsy from the left axilla yielded a diagnosis of MCD. Cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) were administered for a total of 4 cycles. The patient's fever and lymphadenopathy resolved after the course of chemotherapy. She has been in complete remission for 24 months at this writing. As previously reported, this case report suggests that MCD can develop without viral infection. CHOP chemotherapy may be an effective treatment option for newly diagnosed MCD patients.
 ...
PMID:Complete remission in a patient with human herpes virus-8 negative multicentric Castleman disease using CHOP chemotherapy. 1970 9

Systemic sclerosis (SSc) is a progressive and often devastating disease characterized by autoimmune dysfunction, vasculopathy, and fibrosis. Interstitial lung disease (ILD) is identified in the majority of patients with SSc and is the leading cause of SSc-related mortality. Although clinical manifestations and ILD severity vary among patients, lung function typically declines to the greatest extent during the first 3-4 years after disease onset. We aim to provide an overview of SSc-associated ILD (SSc-ILD) with a focus on current and emerging tools for early diagnosis of ILD and current and novel treatments under investigation. Early detection of ILD provides the opportunity for early therapeutic intervention, which could improve patient outcomes. Thoracic high-resolution computed tomography is the most effective method of identifying ILD in patients with SSc; it enables detection of mild lung abnormalities and plays an important role in monitoring disease progression. Cyclophosphamide and mycophenolate mofetil are the most commonly prescribed treatments for SSc-ILD. Recently, nintedanib (an antifibrotic) was approved by the Food and Drug Administration for patients with SSc-ILD; it is indicated for slowing the rate of decline in pulmonary function. However, there is a need for additional effective and well-tolerated disease-modifying therapy. Ongoing studies are evaluating other antifibrotics and novel agents. We envision that early detection of lung involvement, combined with the emergence and integration of novel therapies, will lead to improved outcomes in patients with SSc-ILD.
 ...
PMID:Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention. 3184 43